Filter Results
:
(3)
Show Results For
-
All HBS Web
(55)
- Faculty Publications (3)
Show Results For
-
All HBS Web
(55)
- Faculty Publications (3)
Page 1 of
3
Results
- September 2020 (Revised October 2020)
- Case
Moderna (A)
By: Marco Iansiti, Karim R. Lakhani, Hannah Mayer and Kerry Herman
In summer 2020, Stephane Bancel, CEO of biotech firm Moderna, faces several challenges as his company races to develop a vaccine for COVID-19. The case explores how a company builds a digital organization, and leverages artificial intelligence and other digital...
View Details
Keywords:
Covid-19;
Vaccine;
Digital Organizations;
Organizational Structure;
Operations;
Management;
Health Pandemics;
Research And Development;
Goals And Objectives
Iansiti, Marco, Karim R. Lakhani, Hannah Mayer, and Kerry Herman. "Moderna (A)." Harvard Business School Case 621-032, September 2020. (Revised October 2020.)
- September–October 2020
- Article
The Past, Present, and (Near) Future of Gene Therapy and Gene Editing
By: Julia Pian, Amitabh Chandra and Ariel Dora Stern
Emerging gene therapy and gene-editing technologies will have a growing impact on patient lives and health-care delivery. We analyzed a decade of data on clinical trials and venture capital investments to understand the likely trajectory of genetically focused...
View Details
Keywords:
Gene Therapy;
Gene Editing;
Impact;
Health Care And Treatment;
Technological Innovation;
Health Testing And Trials;
Venture Capital;
Change
Pian, Julia, Amitabh Chandra, and Ariel Dora Stern. "The Past, Present, and (Near) Future of Gene Therapy and Gene Editing." NEJM Catalyst Innovations in Care Delivery 1, no. 5 (September–October 2020).
- October 2016 (Revised September 2017)
- Case
The CRISPR-Cas9 Quarrel
By: Richard G. Hamermesh and Matthew G. Preble
In mid-2016, the Broad Institute and the University of California, Berkeley were in the middle of a contentious patent dispute over which entity controlled a breakthrough gene editing technology called CRISPR-Cas9. With CRISPR-Cas9, scientists might soon be able to...
View Details
Keywords:
Crispr;
Broad Institute;
University Of California Berkeley;
Intellectual Property;
Patents;
Law;
Lawsuits And Litigation;
Science;
Genetics;
Entrepreneurship;
Biotechnology Industry;
United States
Hamermesh, Richard G., and Matthew G. Preble. "The CRISPR-Cas9 Quarrel." Harvard Business School Case 817-020, October 2016. (Revised September 2017.)